GlassScriptPhysician profile
Kacey Nguyen Lyons
NPI 1598544777
$19,550.82
in general payments reported to CMS, 2019-2025
18 companies · $6,922 in 2025
The $6,922 reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $58.07 · 2024: $13K · 2025: $6,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $5,516 · Food and Beverage: $3,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,185.00 |
| Travel and Lodging | $5,515.70 |
| Food and Beverage | $3,850.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16,826.85 | 2024-2025 | Voquezna |
| Abbvie INC. | $691.57 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $379.13 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Madrigal Pharmaceuticals | $367.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $279.53 | 2024-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $170.93 | 2025 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.28 | 2024-2025 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $146.85 | 2024-2025 | |
| Organon LLC | $137.05 | 2024-2025 | Hadlima, Renflexis |
| Novo Nordisk INC | $109.48 | 2025 | Ozempic |
| Ardelyx, INC. | $75.14 | 2023-2025 | Ibsrela |
| Napo Pharmaceuticals INC | $38.97 | 2025 | Mytesi |
| Mirum Pharmaceuticals, INC. | $34.44 | 2025 | Livmarli |
| Evoke Pharma, INC. | $33.61 | 2024 | |
| Lilly USA, LLC | $33.35 | 2025 | Omvoh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $31.57 | 2025 | Calquence |
| Merck Sharp & Dohme LLC | $21.18 | 2024 | Dificid |
| Pfizer INC. | $18.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacey Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.